Asbestos HUB: News & Reports

  • Asbestos & Mesothelioma Information
  • Free Case Evaluation
  • Attorney Tom Lamb
  • About Asbestos HUB
  • Asbestos-Mesothelioma.com Website

Disappointment Over Immunotherapy in Mesothelioma

November 18, 2019 By Tom Lamb Leave a Comment

Despite showing promise in phase 2 trials, new results from a randomized phase 3 [ immunotherapy in mesothelioma ] trial are disappointing in a tumor type that remains a major killer. In patients with malignant pleural mesothelioma (MPM) who had progressed after first-line chemotherapy, immunotherapy with pembrolizumab (Keytruda, Merck) appears … [Read more...]

Filed Under: Medicine Tagged With: Keytruda, malignant mesothelioma, mesothelioma, mesothelioma treatment, Pembrolizumab

Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds

November 5, 2019 By Tom Lamb Leave a Comment

Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show. Although more of these advanced cancer patients responded to Keytruda than to … [Read more...]

Filed Under: Medicine Tagged With: Keytruda, malignant mesothelioma, malignant pleural mesothelioma, mesothelioma treatment, Pembrolizumab

Immunotherapy Making Headway in SCLC and Mesothelioma

March 20, 2018 By Tom Lamb Leave a Comment

Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD. The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, … [Read more...]

Filed Under: Medicine Tagged With: asbestos-cancer, immunotherapy, lung cancer, malignant mesothelioma, mesothelioma, mesothelioma treatment, nivolumab, Pembrolizumab

Clinical Safety and Activity of Pembrolizumab in Patients With Malignant Pleural Mesothelioma

March 21, 2017 By Tom Lamb Leave a Comment

BACKGROUND  Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death … [Read more...]

Filed Under: Medicine Tagged With: asbestos-cancer, malignant mesothelioma, mesothelioma, mesothelioma treatment, Pembrolizumab, pleural-mesothelioma

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Asbestos Legal Watch

TJL@LambLawOffice.com

Phone: 800-426-9535

Wilmington, North Carolina

MAIN NAVIGATION MENU

  • Asbestos & Mesothelioma
  • Free Case Evaluation
  • Attorney Tom Lamb
  • About Asbestos HUB
  • More Information

Categories

  • Claims (183)
  • Exposure (314)
  • Facts (248)
  • Law (249)
  • Lawsuits (235)
  • Medicine (288)

Our Other Websites

Asbestos & Mesothelioma
Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Asbestos & Mesothelioma Information
  • Disclaimer And Copyright

Copyright © 2019 · Law Offices of Thomas J. Lamb, P.A.